Follow The Filings

PNTG Pennant Group Inc.

Health Care, filed as PENNANT GROUP INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $21M
  • 1 add

In 2026 Q2 First Eagle Investment Management added to Pennant Group.

Who owns this now

Largest portfolio weights among holders, up to 0.0% (First Eagle Investment Management). Not free-float ownership.

  1. First Eagle Investment Manage... Add 0.04%

Who owns PNTG

Sorted by value, long equity only, as of 2026 Q2.

History
First Eagle Investment Management 0.04%, was 0.03% Add +32.4% 570,500 $21M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PNTG's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PNTG insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $690K sold by 3 insiders under 10b5-1 plans
  1. Jason Paul Steik Chief Clinical Officer
    Planned sale
    $54K 1,394 shares at $38.52 8.4% of stake
    Traded Aug 6 Filed Aug 10
    ↗
  2. Brent Guerisoli CEO
    Planned sale
    $165K 4,285 shares at $38.52 4.1% of stake
    Traded Aug 6 Filed Aug 10
    ↗
  3. Kirk Sterling Cheney EVP, GC and Corp Secy
    Planned sale
    $54K 1,393 shares at $38.52 7% of stake
    Traded Aug 6 Filed Aug 10
    ↗
  4. Brent Guerisoli CEO
    Planned sale
    $131K 3,159 shares at $41.57 3% of stake
    Traded Jul 10 Filed Jul 14
    ↗
  5. Brent Guerisoli CEO
    Planned sale
    $128K 3,165 shares at $40.51 3% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  6. Brent Guerisoli CEO
    Planned sale
    $158K 4,508 shares at $35.08 4.4% of stake
    Traded May 22 Filed May 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 32 stock grants and 5 option exercises.

SEC filings

Recent issuer filings from EDGAR, 9 shown.

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $544.89M $695.24M $947.7M
Net income $13.38M $22.56M $29.58M
Net margin * 2.5% 3.2% 3.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $80.08M $122.86M $167.41M
Total non-current assets * $459.61M $556.66M $800.77M
Total assets $539.69M $679.52M $968.18M
Total current liabilities $71.55M $101.7M $147.26M
Total non-current liabilities * $322.63M $265.86M $446.66M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $33.09M $39.3M $48.29M
Cash from investing -$30.22M -$70.68M -$227.97M
Cash from financing $1.11M $49.57M $172.46M
Net change in cash $3.98M $18.19M -$7.22M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.